GlassScriptPhysician profile
Mark R Heimmel
NPI 1942427125
$1,118.79
in general payments reported to CMS, 2019-2025
25 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $111 · 2021: $79.85 · 2022: $353 · 2023: $120 · 2024: $114 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $346.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $237.84 | 2019-2025 | Clareon, Clareon Panoptix Pro |
| Biotissue Holdings INC. | $160.39 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $111.17 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $78.85 | 2021-2023 | Tecnis Iol |
| Rxsight INC | $56.56 | 2024 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Abbvie INC. | $45.94 | 2022-2023 | |
| Sight Sciences, INC. | $39.73 | 2019-2025 | Omni Surgical System |
| Ocular Therapeutix, INC. | $38.87 | 2024-2025 | Dextenza |
| Apellis Pharmaceuticals, INC. | $34.81 | 2022 | |
| Bausch & Lomb Americas INC. | $30.98 | 2022-2023 | Envista Mx60 Iol |
| Allergan, INC. | $27.85 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $26.85 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.14 | 2019-2020 | |
| Genentech USA, INC. | $24.26 | 2019 | |
| Coopervision INC. | $23.36 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $20.69 | 2022 | |
| Alimera Sciences, INC. | $18.44 | 2021 | |
| Horizon Therapeutics Plc | $17.28 | 2023 | Tepezza |
| Dompe US, INC. | $16.85 | 2024 | Oxervate |
| Omeros Corporation | $15.34 | 2019 | |
| Aerie Pharmaceuticals, INC. | $14.98 | 2021 | |
| Oyster Point Pharma, INC. | $14.94 | 2022 | |
| Eyepoint US, INC. | $14.27 | 2019 | |
| Sun Pharmaceutical Industries INC. | $12.28 | 2019 | |
| New World Medical,INC. | $11.12 | 2024 | Streamline, Kahook Dual Blade, Clearpath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Heimmel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.